Maintenance Hormonal Therapy and DLBCL

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2029

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Tamoxifen 20mg

maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT

All Listed Sponsors

lead

Sohag University

OTHER

NCT06355401 - Maintenance Hormonal Therapy and DLBCL | Biotech Hunter | Biotech Hunter